Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1007762

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has targets for improvements to care and services for people with dementia over the period of this Parliament.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	191881
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>Dementia remains a key priority for the Government. We will implement the Prime Minister’s Challenge on Dementia 2020 (published in February 2015) in full to make sure the lives of those with dementia are transformed by 2020.</p><p> </p><p>Working with our partners, we continue to make progress against the ambitions set in the March 2016 Implementation Plan which details how the commitments in the Challenge, across the four core themes of risk reduction, health and care, awareness and social action, and research will be met. This is reflected in the specific expectation set in the mandate to NHS England 2018/19 that two thirds of people living with dementia should receive a formal diagnosis. As of October 2018, the dementia diagnosis rate was 67.9%.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 20/11/2018 15:37:58 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1409 label Biography information for Mr Gregory Campbell

1005674

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Electronic Cigarettes: Regulation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether (a) nicotine shots and (b) shortfills are regulated under (i) UK and (ii) EU law.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	190468
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>Nicotine shots are regulated under the Tobacco and Related Products Regulation 2016 as they are a nicotine containing product. As shortfills do not contain nicotine when sold they are not regulated under the Tobacco and Related Products Regulations 2016 (TRPR), but are covered by General Product Safety Regulations.</p><p> </p><p>The Government is committed to conduct a review of the TRPR at a later date.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 190469 question first answered 20/11/2018 15:23:24 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

1005675

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Electronic Cigarettes
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the (a) effectiveness of the regulation of non-nicotine liquid for vape products and (b) effect on public health of (i) shortfills and (ii) nicotine shots.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	190469
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>Nicotine shots are regulated under the Tobacco and Related Products Regulation 2016 as they are a nicotine containing product. As shortfills do not contain nicotine when sold they are not regulated under the Tobacco and Related Products Regulations 2016 (TRPR), but are covered by General Product Safety Regulations.</p><p> </p><p>The Government is committed to conduct a review of the TRPR at a later date.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 190468 question first answered 20/11/2018 15:23:24 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

1005676

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tobacco
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what evidence his Department has collated on effect on people's health of the use of (a) Snus and (b) tobacco.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	190470
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>No evidence has been collated by the Department as snus is banned under the European Union’s Tobacco Products Directive as an oral tobacco product. The Commission has however set out the evidence underpinning the ban. The impact assessment for the 2014 Directive can be found at the following link:</p><p> </p><p><a href="https://ec.europa.eu/health/sites/health/files/tobacco/docs/com_2012_788_ia_en.pdf" target="_blank">https://ec.europa.eu/health/sites/health/files/tobacco/docs/com_2012_788_ia_en.pdf</a></p><p> </p><p>The Government committed in the Tobacco Control Plan for England to review where the United Kingdom’s exit from the EU offers us opportunities to re-appraise current regulation to ensure this continues to protect the nation’s health. We will look to identify where we can sensibly deregulate without harming public health or where current EU regulations limit our ability to deal with tobacco. The Government’s goal will remain to achieve a proportionate approach to managing risk, one which protects the young and non-smokers, whilst giving smokers access to products which will reduce harm.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 190471 190472 question first answered 20/11/2018 15:22:24 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

1005677

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Oral Tobacco
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make it his policy to direct Public Health England to include the effect of Snus on people's health in future evidence reviews.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	190471
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>No evidence has been collated by the Department as snus is banned under the European Union’s Tobacco Products Directive as an oral tobacco product. The Commission has however set out the evidence underpinning the ban. The impact assessment for the 2014 Directive can be found at the following link:</p><p> </p><p><a href="https://ec.europa.eu/health/sites/health/files/tobacco/docs/com_2012_788_ia_en.pdf" target="_blank">https://ec.europa.eu/health/sites/health/files/tobacco/docs/com_2012_788_ia_en.pdf</a></p><p> </p><p>The Government committed in the Tobacco Control Plan for England to review where the United Kingdom’s exit from the EU offers us opportunities to re-appraise current regulation to ensure this continues to protect the nation’s health. We will look to identify where we can sensibly deregulate without harming public health or where current EU regulations limit our ability to deal with tobacco. The Government’s goal will remain to achieve a proportionate approach to managing risk, one which protects the young and non-smokers, whilst giving smokers access to products which will reduce harm.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 190470 190472 question first answered 20/11/2018 15:22:24 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

1005678

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Oral Tobacco
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of lifting the ban on Snus products.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	190472
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>No evidence has been collated by the Department as snus is banned under the European Union’s Tobacco Products Directive as an oral tobacco product. The Commission has however set out the evidence underpinning the ban. The impact assessment for the 2014 Directive can be found at the following link:</p><p> </p><p><a href="https://ec.europa.eu/health/sites/health/files/tobacco/docs/com_2012_788_ia_en.pdf" target="_blank">https://ec.europa.eu/health/sites/health/files/tobacco/docs/com_2012_788_ia_en.pdf</a></p><p> </p><p>The Government committed in the Tobacco Control Plan for England to review where the United Kingdom’s exit from the EU offers us opportunities to re-appraise current regulation to ensure this continues to protect the nation’s health. We will look to identify where we can sensibly deregulate without harming public health or where current EU regulations limit our ability to deal with tobacco. The Government’s goal will remain to achieve a proportionate approach to managing risk, one which protects the young and non-smokers, whilst giving smokers access to products which will reduce harm.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 190470 190471 question first answered 20/11/2018 15:22:24 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

1005714

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sapropterin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to NHS England’s appraisal of Kuvan, what steps his Department is taking to ensure that the cost offset of dietary treatments is considered in its economic assessment of the cost of commissioning new medicines.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	190518
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>NHS England has considered a policy for Kuvan (sapropterin) at the Clinical Priorities Advisory Group (CPAG) meeting on 6/7 November. Whilst NHS England did make an estimate of the current cost of protein supplements and a potential reduction in their use if Kuvan were prescribed, this cost was not included in the analysis because commissioning responsibility for supplements rests with clinical commissioning groups and it would be unlikely that NHS England would be able to realise these savings. The cost of the potential reduction in protein supplements is also relatively modest compared to the cost of Kuvan.</p><p> </p><p>In line with its published process, the recommendations from CPAG will be considered by the Specialised Commissioning Oversight Group and the Specialised Services Commissioning Committee. A decision about whether or not Kuvan has been prioritised for funding will be published in due course.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Kuvan for the treatment of phenylketonuria. In developing technology appraisal guidance, NICE takes into account all the health and publicly funded social care related costs and benefits associated with the treatment, potentially including any costs from NHS funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 190519 question first answered 20/11/2018 15:25:36 answering member 4067 label Biography information for Steve Brine
tabling member	4523 label Biography information for Catherine West

1005715

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sapropterin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the financial cost offset to the NHS including savings to the NHS from reduced acquisition costs of food supplements of commissioning Kuvan for the treatment of phenylketonuria.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	190519
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>NHS England has considered a policy for Kuvan (sapropterin) at the Clinical Priorities Advisory Group (CPAG) meeting on 6/7 November. Whilst NHS England did make an estimate of the current cost of protein supplements and a potential reduction in their use if Kuvan were prescribed, this cost was not included in the analysis because commissioning responsibility for supplements rests with clinical commissioning groups and it would be unlikely that NHS England would be able to realise these savings. The cost of the potential reduction in protein supplements is also relatively modest compared to the cost of Kuvan.</p><p> </p><p>In line with its published process, the recommendations from CPAG will be considered by the Specialised Commissioning Oversight Group and the Specialised Services Commissioning Committee. A decision about whether or not Kuvan has been prioritised for funding will be published in due course.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Kuvan for the treatment of phenylketonuria. In developing technology appraisal guidance, NICE takes into account all the health and publicly funded social care related costs and benefits associated with the treatment, potentially including any costs from NHS funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 190518 question first answered 20/11/2018 15:25:36 answering member 4067 label Biography information for Steve Brine
tabling member	4523 label Biography information for Catherine West

1005716

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether a single technology appraisal process or a highly specialised technology appraisal process is used for (a) phenylketonuria and (b) other rare diseases.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	190520
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>Medicines and other treatments being considered for assessment by the National Institute for Health and Care Excellence (NICE) are considered through an established topic selection process to ensure that they are suitable for referral to NICE and that they are routed to the most appropriate process within NICE. The topic selection process includes consideration of topic against published criteria and consultation with stakeholders. Most new medicines are referred for assessment through NICE’s technology appraisal programme though NICE also operates a separate highly specialised technology evaluation programme for a small number of very high cost drugs for the treatment of very rare diseases. Following consideration through the topic selection process, NICE is currently developing guidance on two drugs for the treatment of phenylketonuria through its technology appraisal programme.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/11/2018 15:26:35 answering member 4067 label Biography information for Steve Brine
tabling member	4523 label Biography information for Catherine West

1005747

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Children and Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will set up a Young Patient Travel Fund to assist families with the travel expense of attending specialist hospitals for cancer treatment; and if he will make a statement.
tabling member constituency	Brighton, Pavilion
tabling member printed	Caroline Lucas
uin	190424
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>There is work underway to review the service specifications for children and young people with cancer. This will provide an opportunity to consider how some aspects of the patient pathway may be provided more locally to reduce the travel burden for patients and their families.</p><p> </p><p>Currently the Healthcare Travel Costs Scheme which is part of the NHS Low Income Scheme allows for patients (and in certain circumstances their carers) to receive reimbursement of travel if they are in receipt of a qualifying benefit or on a low income. The NHS Low Income Scheme has helped 337,000 applicants to receive financial help with their National Health Service treatment.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/11/2018 15:24:06 answering member 4067 label Biography information for Steve Brine
tabling member	3930 label Biography information for Caroline Lucas